Dane Leone
Stock Analyst at Raymond James
(1.17)
# 3,810
Out of 5,130 analysts
69
Total ratings
33.96%
Success rate
-6.46%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $7.99 | +137.80% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.68 | +488.24% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $14.59 | +208.43% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $118.64 | -74.71% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $796.55 | +19.26% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.09 | +522.01% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $77.25 | -40.45% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $33.11 | +108.40% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.35 | +49.53% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $11.26 | +24.33% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $13.89 | +317.57% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $19.60 | +257.14% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.71 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $62.51 | +0.78% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $55.86 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.83 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $76.87 | -15.44% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $326.10 | -21.80% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.02 | +696.02% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $204.39 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $7.99
Upside: +137.80%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.68
Upside: +488.24%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $14.59
Upside: +208.43%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $118.64
Upside: -74.71%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $796.55
Upside: +19.26%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.09
Upside: +522.01%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $77.25
Upside: -40.45%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $33.11
Upside: +108.40%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.35
Upside: +49.53%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $11.26
Upside: +24.33%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $13.89
Upside: +317.57%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $19.60
Upside: +257.14%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $62.51
Upside: +0.78%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $55.86
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.83
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $76.87
Upside: -15.44%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $326.10
Upside: -21.80%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.02
Upside: +696.02%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $204.39
Upside: -